WuXi Biologics Retains FTSE4Good Status for Sixth Consecutive Year

The FTSE4Good Index Series, managed by London Stock Exchange Group’s FTSE Russell, serves as a primary benchmark for investors prioritizing sustainability. WuXi Biologics earned this year's distinction by maintaining high performance in corporate governance, labor standards, and environmental management. These metrics are central to the firm's Green CRDMO strategy, which aims to reduce the carbon footprint and lifecycle environmental impact of drug development for its international partners.

Dr. Chris Chen, CEO and chair of the company’s ESG committee, stated that the recognition reinforces the firm’s strategy to bake sustainability into its long-term business growth. Beyond the FTSE4Good index, the organization holds an AAA rating from MSCI and a Platinum Medal from EcoVadis. As of April 2026, the company supports 982 active client projects, leveraging digital infrastructure to drive efficiency across its facilities in China, the United States, Ireland, Germany, and Singapore.